news
GSK announces data from five Phase III studies of albiglutide
24 June 2013 | By GlaxoSmithKline
Data from five long-term Phase III studies comparing albiglutide...
List view / Grid view
GlaxoSmithKline (GSK)
news
GSK receives offer for its thrombosis brands and related manufacturing site
18 June 2013 | By GlaxoSmithKline
GlaxoSmithKline has received an offer for its thrombosis brands...
article
Chemometrics: Implementing multivariate data analysis to monitor mammalian cell culture processes
13 June 2013 | By Payal Roychoudhury, formerly AstraZeneca and Ronan O’Kennedy, Fujifilm Diosynth Biotechologies and Jim Faulkner, GlaxoSmithKline and Brian McNeil & Linda M. Harvey, University of Strathclyde
Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that offer benefits such as shorter time lines, improved consistency, higher monoclonal antibody (mAb) production, better genetic stability and increased flexibility. Each of these advantages extends a potentially large cost benefit to companies as their recombinant protein products…
news
GSK statement in response to FDA Advisory Committee’s vote on availability of Avandia (rosiglitazone)
6 June 2013 | By GlaxoSmithKline
A joint advisory committee to the U.S. FDA voted to continue to make Avandia available...
news
GSK announces Phase III data for TYKERB/TYVERB® (lapatinib) in combination with chemotherapy for advanced HER2-positive gastric cancer
3 June 2013 | By GlaxoSmithKline
Study did not meet the primary endpoint...
news
GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following chemotherapy in women with advanced epithelial ovarian cancer
1 June 2013 | By GlaxoSmithKline
GSK announced that its Phase III clinical trial of VOTRIENT...
news
GSK strengthens vaccines business with acquisition of Okairos
29 May 2013 | By GlaxoSmithKline
GSK has acquired Okairos AG, a specialist developer of vaccine platform technologies for €250 million in cash...
news
Two new GSK oral oncology treatments approved by FDA
29 May 2013 | By GlaxoSmithKline
BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets approved by FDA...
news
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics
23 May 2013 | By GlaxoSmithKline
Funding will support development of drugs to fight antibiotic resistance and bioterrorism...
news
BREO™ ELLIPTA™ gains US approval for the treatment of COPD
10 May 2013 | By GlaxoSmithKline
GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™...
news
GSK and Save the Children form unique partnership to save the lives of one million children
9 May 2013 | By GlaxoSmithKline
Working together to accelerate the availability of two children’s medicines...
news
GSK enters new commitment with the GAVI Alliance to supply cervical cancer vaccine for girls in the world’s poorest countries
9 May 2013 | By GlaxoSmithKline
GSK's new commitment to the GAVI Alliance...
news
Funding boost for GSK’s open innovation research into diseases affecting the developing world
3 May 2013 | By GlaxoSmithKline
GlaxoSmithKline announced a funding injection of up to £5m from the Wellcome Trust...
news
GlaxoSmithKline and Impax Pharmaceuticals terminate their collaboration on IPX066
29 April 2013 | By GlaxoSmithKline
GSK and Impax Pharmaceuticals announced that they are terminating their collaboration...
news
GSK announces regulatory submission for umeclidinium monotherapy in European Union
29 April 2013 | By GlaxoSmithKline
UMEC is an investigational bronchodilator molecule...
